summittxinc.com - SMMT Real Price to Acquire Entire Company

Summit Therapeutics (SMMT) is building high-yield therapeutic foundations through innovative cancer and infection drugs protected by long-term patents. The price indicator on the Enterprise Value chart is fixed at 11558.89. Summit Therapeutics (SMMT) attracts bold specialists via aggressive option schemes and accelerates development efficiency by implementing robotic screening systems and automated clinical data analysis.

SMMT (summittxinc.com) Total Company Value history from 11/23/2025 to 10/28/2026

Summit Therapeutics (SMMT) - metric breakdowns and financial figures

- price and consensus price forecast:

Stock Quotes Summit Therapeutics plc|SMMT - Price Target Chart

- market capitalization data:

Market Valuation Summit Therapeutics|SMMT - Real Price to Acquire Entire Company

- book capitalization data:

Book Price of a Share Summit Therapeutics|SMMT - Company Book Value|Market Capitalization to Net Assets summittxinc.com|SMMT - Company Total Assets

- debt and liquidity data:

All Debt to Shareholders' Equity Ratio Summit Therapeutics|SMMT - Long-Term Debt to Capital|Short-Term Debt to Capital summittxinc.com|SMMT - Company Debts|Debt to Net Assets Ratio Summit Therapeutics

Comprehensive company analysis:Summit Therapeutics plc (SMMT)

This metric is calculated as the sum of market capitalization and net debt, reflecting the actual cost of acquiring the entire business after accounting for liquid assets. Given the single-product dependency of Summit Therapeutics (SMMT) on a single antibody, the trend in the company's total fundamental value demonstrates the extent to which the market currently prices in the success of clinical trials into the current enterprise value.

Competitor analysis for Summit Therapeutics

Moderna Inc - Real Price to Acquire Entire Company|PCVX: Total Company Value|Tarsus Corp (TARS) - Real Price to Acquire Entire Company|CRMD - Real Price to Acquire Entire Company|MCRB (serestherapeutics.com) - Aggregate Business Value|Total Company Value Spero Therapeutics, Inc. SPRO|Full Business Value Scynexis|AN2 Therapeutics, Inc. (ANTX) - Enterprise Value|Value Adjusted for Debt and Cash polypid.com (PYPD)|Enterprise Value LSB (LakeShore Biopharma Co.)|Iterum Therapeutics PLC - Enterprise Value|Total Company Value BiomX Ltd (PHGE)|SNGX: Value Adjusted for Debt and Cash|SXTP (60degreespharma.com) - Total Company Value|oragenics.com (OGEN) - Real Price to Acquire Entire Company|ONCO (Onconetix, Inc.) - Enterprise Value|Enterprise Value opgen.com (OPGN)